Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
At least for solid tumors the promising results from preclinical studies of systemic and on-site IL-12-based therapy did not prevail in clinical studies. In future combinatorial approaches using IL-12 together with other cytokines or antiangiogenic molecules have to be evaluated. This review focuses on anticancer effects of the IL-12 family in preclinical and clinical studies with an emphasis on colorectal cancer.
Keywords: Anticancer; Burkitt's lymphoma; CD4+; CD8+; COLON CARCINOMA; Colorectal Cancer; Colorectal cancer; EBI3; Epstein-Barr virus-induced gene 3; IL-12; IL-12 family; IL-12-based therapy; IL-12R1; IL-12Rb1; IL-12Rb2; IL-17; IL-23; IL-27; IL-35; IL-6; IL12p70; IP-10; JAK; Janus kinases; Listeria-induced macrophages; MIG; Müllerian carcinoma; NK-T cells; STAT; T cells; T-bet tran-scription factor; TH1 T cell; Tyrosin Kinase; angiopoietin 2; antiangiogenic; antiangiogenic factors; antigen-presenting cells (APCs); colon tumor; differentiation; encephalomyelitis; gp130; heterodimeric complexes; interferon (IFN)-; interferon-inducible protein (IP); interleukin (IL)-12; interleukins; intracellular pathogens; matrix metallo-proteinase (MMP); monocyte chemoattractant protein; natural killer (NK); natural killer-stimulating factor; p28; p35; p40; pathogen-associated molecular patterns (PAMPs); tumorigenesis
Document Type: Research Article
Publication date: 01 October 2010
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.